{
    "root": "efd93579-94a9-4501-9b72-a0ec2e71b8e7",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Fenofibrate",
    "value": "20250310",
    "ingredients": [
        {
            "name": "FENOFIBRATE",
            "code": "U202363UOS"
        },
        {
            "name": "CROSPOVIDONE (15 MPA.S AT 5%)",
            "code": "68401960MK"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "HYPROMELLOSE 2910 (3 MPA.S)",
            "code": "0VUT3PMY82"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POLACRILIN POTASSIUM",
            "code": "0BZ5A00FQU"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        }
    ],
    "indications": "fenofibrate peroxisome proliferator-activated receptor ( ppar ) alpha agonist indicated adjunct diet : reduce elevated ldl-c , total-c , tg apo b , increase hdl-c adult patients primary hypercholesterolemia mixed dyslipidemia ( 1.1 ) . treatment adult patients severe hypertriglyceridemia ( 1.2 ) . limitations : fenofibrate shown reduce coronary heart disease morbidity mortality patients type 2 diabetes mellitus ( 5.1 ) .",
    "contraindications": "primary hypercholesterolemia mixed dyslipidemia : initial dose 145 mg daily ( 2.2 ) . severe hypertriglyceridemia : initial dose 48 145 mg daily . maximum dose 145 mg ( 2.3 ) . renally impaired patients : initial dose 48 mg daily ( 2.4 ) . geriatric patients : select dose basis renal function ( 2.5 ) may taken without regard meals ( 2.1 ) .",
    "warningsAndPrecautions": "fenofibrate tablets usp available two strengths : 48 mg , white white-off oval shaped tablets debossed `` lu `` one side `` b21 `` side . supplied follows : ndc 68180-388-09 bottles 90 's 145 mg , white off-white oval shaped tablets debossed `` lu `` one side `` b22 `` side . supplied follows : ndc 68180-389-09 bottles 90 's ndc 68180-389-02 bottles 500 's storage store 25\u00b0c ( 77\u00b0f ) ; excursions permitted 15 30\u00b0c ( 59 86\u00b0f ) [ usp controlled room temperature ] . keep reach children . protect moisture .",
    "adverseReactions": "severe renal dysfunction , including dialysis patients ( 4 , 8.6 , 12.3 ) . active liver disease ( 4 , 5.2 ) . gallbladder disease ( 4 , 5.5 ) . known hypersensitivity fenofibrate ( 4 ) . nursing mothers ( 4 , 8.2 ) .",
    "indications_original": "Fenofibrate is a peroxisome proliferator-activated receptor (PPAR) alpha agonist indicated as an adjunct to diet: To reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia ( 1.1 ). For treatment of adult patients with severe hypertriglyceridemia ( 1.2 ). Limitations of Use: Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus ( 5.1 ).",
    "contraindications_original": "Primary hypercholesterolemia or mixed dyslipidemia: Initial dose of 145 mg once daily ( 2.2 ). Severe hypertriglyceridemia: Initial dose of 48 to 145 mg once daily. Maximum dose is 145 mg ( 2.3 ). Renally impaired patients: Initial dose of 48 mg once daily ( 2.4 ). Geriatric patients: Select the dose on the basis of renal function ( 2.5 ) May be taken without regard to meals ( 2.1 ).",
    "warningsAndPrecautions_original": "Fenofibrate tablets USP are available in two strengths:\n                  48 mg, white to white-off oval shaped tablets debossed with \"LU\" on one side and \"B21\" on the other side.\n                  They are supplied as follows:\n                  NDC 68180-388-09 Bottles of 90's\n                  145 mg, white to off-white oval shaped tablets debossed with \"LU\" on one side and \"B22\" on the other side.\n                  They are supplied as follows:\n                  NDC 68180-389-09 Bottles of 90's \n                  NDC 68180-389-02 Bottles of 500's\n                  \n                     Storage\n                  \n                  Store at 25\u00b0C (77\u00b0F); excursions permitted to 15 to 30\u00b0C (59 to 86\u00b0F) [see USP Controlled Room Temperature]. Keep out of the reach of children. Protect from moisture.",
    "adverseReactions_original": "Severe renal dysfunction, including dialysis patients ( 4 , 8.6 , 12.3 ). Active liver disease ( 4 , 5.2 ). Gallbladder disease ( 4 , 5.5 ). Known hypersensitivity to fenofibrate ( 4 ). Nursing mothers ( 4 , 8.2 )."
}